Compounds > 1-arabinofuranosylcytosine-5--stearylphosphate

1-arabinofuranosylcytosine-5--stearylphosphate and Leukemia--Myelomonocytic--Acute

1-arabinofuranosylcytosine-5--stearylphosphate has been researched along with Leukemia--Myelomonocytic--Acute* in 2 studies

Other Studies

2 other study(ies) available for 1-arabinofuranosylcytosine-5--stearylphosphate and Leukemia--Myelomonocytic--Acute

Article	Year
[Low-dose cytarabine ocfosfate therapy in an elderly acute myelogenous leukemia]. Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:6 A 71-year-old man was admitted for severe anemia. Bone marrow puncture revealed 48% of blast cells. A diagnosis of acute myelogenous leukemia (AML-M 4) was made. As the patient was old, we administered 300mg of cytarabine ocfosfate (SPAC) for 21 days. Blast cells in bone marrow decreased 5.6%, and SPAC was considered effective. We treated him with the same dose of SPAC for 14 days after a 21-day interval from the end of the first treatment. Although leukemic cells were still seen in bone marrow after two treatments, we considered him in partial remission, and he was discharged. After discharge, the hematological findings remain almost normal with intermittent treatment of 150 mg of SPAC for over one year. Thus, cytarabine ocfosfate might be useful in elderly AML patients. Topics: Aged; Antineoplastic Agents; Arabinonucleotides; Bone Marrow; Cell Count; Cytidine Monophosphate; Drug Administration Schedule; Humans; Leukemia, Myelomonocytic, Acute; Male	1995
[Successful treatment of acute myelomonocytic leukemia developed from MDS with cytarabine ocfosfate (SPAC)]. Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:3 A 65-year-old female with acute myelomonocytic leukemia (AMMoL) developed from myelodysplastic syndrome (MDS), successfully treated with cytarabine ocfosfate (SPAC) is reported. Ubenimex, calcitriol and corticosteroid had a minor effect on her MDS. Since she had severe anemia and congestive heart failure on developing leukemia, she was treated with oral administration of SPAC, a cytidine deaminase resistant derivative of Ara-C. After the second course of SPAC (200 mg/day, for 14-28 days), marked erythroid bursts were found and she entered complete remission. The samplings of SPAC and its metabolites of SPAC were investigated in 2 cases including this case, but there seemed to be no relation between their content and effects. In AML patients, especially in cases developed from MDS, SPAC might be useful because it can be given orally even in an outpatient. Topics: Aged; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Drug Administration Schedule; Female; Humans; Leukemia, Myelomonocytic, Acute; Myelodysplastic Syndromes; Remission Induction	1995

Article

Year

[Low-dose cytarabine ocfosfate therapy in an elderly acute myelogenous leukemia].

Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:6

A 71-year-old man was admitted for severe anemia. Bone marrow puncture revealed 48% of blast cells. A diagnosis of acute myelogenous leukemia (AML-M 4) was made. As the patient was old, we administered 300mg of cytarabine ocfosfate (SPAC) for 21 days. Blast cells in bone marrow decreased 5.6%, and SPAC was considered effective. We treated him with the same dose of SPAC for 14 days after a 21-day interval from the end of the first treatment. Although leukemic cells were still seen in bone marrow after two treatments, we considered him in partial remission, and he was discharged. After discharge, the hematological findings remain almost normal with intermittent treatment of 150 mg of SPAC for over one year. Thus, cytarabine ocfosfate might be useful in elderly AML patients.

Topics: Aged; Antineoplastic Agents; Arabinonucleotides; Bone Marrow; Cell Count; Cytidine Monophosphate; Drug Administration Schedule; Humans; Leukemia, Myelomonocytic, Acute; Male

1995

[Successful treatment of acute myelomonocytic leukemia developed from MDS with cytarabine ocfosfate (SPAC)].

Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:3

A 65-year-old female with acute myelomonocytic leukemia (AMMoL) developed from myelodysplastic syndrome (MDS), successfully treated with cytarabine ocfosfate (SPAC) is reported. Ubenimex, calcitriol and corticosteroid had a minor effect on her MDS. Since she had severe anemia and congestive heart failure on developing leukemia, she was treated with oral administration of SPAC, a cytidine deaminase resistant derivative of Ara-C. After the second course of SPAC (200 mg/day, for 14-28 days), marked erythroid bursts were found and she entered complete remission. The samplings of SPAC and its metabolites of SPAC were investigated in 2 cases including this case, but there seemed to be no relation between their content and effects. In AML patients, especially in cases developed from MDS, SPAC might be useful because it can be given orally even in an outpatient.

Topics: Aged; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Drug Administration Schedule; Female; Humans; Leukemia, Myelomonocytic, Acute; Myelodysplastic Syndromes; Remission Induction

1995